Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers

• ClinicalTrials.gov Identifier: NCT00319748
• Recruitment Status: Completed
• First Posted: April 27, 2006
• Results First Posted: September 25, 2009
• Last Update Posted: August 26, 2019
• Sponsor: Masonic Cancer Center, University of Minnesota
• Collaborator: Pfizer
• Information provided by: Masonic Cancer Center, University of Minnesota

Study Description

Brief Summary:

The purpose of this study is to evaluate the anti-tumor activity of 852A when used to treat metastatic breast, ovarian, endometrial or cervical cancer not responding to standard treatment.

Condition or disease	Intervention/treatment	Phase
Breast Cancer; Ovarian Cancer; Endometrial Cancer; Cervical Cancer	Drug: 852A	Phase 2

Detailed Description:

852A will be administered as a subcutaneous injection (SC) 2 times per week for 12 weeks (24 doses) with provisions for dose escalation or reduction based on tolerability.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 15 participants
• Allocation: Non-Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase II Study of 852A Administered Subcutaneously in Patients With Metastatic Refractory Breast, Ovarian, Endometrial and Cervical Cancers
• Study Start Date: April 2006
• Actual Primary Completion Date: December 2007
• Actual Study Completion Date: December 2008

Arms and Interventions

Arm	Intervention/treatment
Experimental: Intent-To-Treat; Patients treated with at least one dose - 852A subcutaneous injection.	Drug: 852A; 0.2% 852a subcutaneous injection, 2 times per week for 12 weeks (24 doses) starting at 0.6 mg/m2; subsequent dose escalation for additional courses may be increased by 0.2 mg/m2 not to exceed 1.2 mg/m2.; Other Names: TLR-7; Toll-like receptor-7
Experimental: Evaluable Cohort; Patients who received all 24 doses of 852A per protocol.	Drug: 852A; 0.2% 852a subcutaneous injection, 2 times per week for 12 weeks (24 doses) starting at 0.6 mg/m2; subsequent dose escalation for additional courses may be increased by 0.2 mg/m2 not to exceed 1.2 mg/m2.; Other Names: TLR-7; Toll-like receptor-7

Outcome Measures

Primary Outcome Measures :

1. Patients With Tumor Response (Response Evaluation Criteria in Solid Tumors) Who Received All 24 Doses of 852A. [ Time Frame: after 12 weeks (24 doses of 852A) ]
   Assessment of anti-tumor activity of 852A using Response Evaluation Criteria in Solid Tumors (RECIST) criteria to evaluate tumor response after 24 doses. Complete Response (CR)= disappearance of all target lesions, Partial Response (PR) = at least 30% decrease in sum of longest diameter of target lesions, Progressive Disease (PD) = at least 25% increase in sum of longest diameter of target lesions, Stable Disease = neither PR or PD.

Secondary Outcome Measures :

1. Mean Difference Values for Interleukin 1 Receptor Antagonist (IKL1ra) [ Time Frame: Prior to Dose 1 and 6 hours after Dose 1 ]
   Measures the difference of IL1ra (cytokine) values as a means of immune activation pre-treatment and 6 hours post-treatment in patients that received at least one dose of study treatment with 852A.
2. Mean Difference Values for 10 kDa Interferon-gamma-induced Protein (IP-10) [ Time Frame: Prior to Dose 1 and 6 Hours Post-Dose ]
   Measures differences in IP-10 (cytokine) values as a means of immune activation pre-treatment and 6 hours post-treatment in patients that received at least one dose of study treatment with 852A.
3. Mean Difference Values for Macrophage Inflammatory Protein-1 Alpha (MIP-1a) [ Time Frame: Prior to Dose 1 and 6 Hours Post-Dose ]
   Measures difference in MIP-1a (cytokine) values as a means of immune activation pre-treatment and 6 hours post-treatment in patients that received at least one dose of study treatment with 852A.
4. Mean Difference Values for Macrophage Inflammatory Protein-1 Beta (MIP-1b) [ Time Frame: Prior to Dose 1 and 6 Hours Post-Dose ]
   Measures difference in Macrophage Inflammatory Protein-1 Beta (cytokine) values as a means of immune activation pre-treatment and 6 hours post-treatment in patients that received at least one dose of study treatment with 852A.
5. Mean Difference Values for Soluble CD40 Ligand (sCD40L) [ Time Frame: Prior to Dose 1 and 6 Hours Post-Dose ]
   Measures difference in Soluble CD40 ligand (cytokine) values as a means of immune activation pre-treatment and 6 hours post-treatment in patients that received at least one dose of study treatment with 852A.
6. Mean Difference Values for Tumor Necrosis Factor-alpha (TNF-a) [ Time Frame: Prior to Dose 1 and 6 Hours Post-Dose ]
   Measures difference in Tumor necrosis factor-alpha (cytokine) values as a means of immune activation pre-treatment and 6 hours post-treatment in patients that received at least one dose of study treatment with 852A.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Adequate performance status:

  • Breast - Karnofsky score > 50;
  • Ovarian, endometrial or cervical - Gynecologic Oncology Group (GOG) performance score ≤2
• If female and of childbearing potential, are willing to use adequate contraception (hormonal, barrier method, abstinence) prior to study entry and for the duration of study participation.
• Normal organ function within 14 days of study entry

• Diagnosis of one of the following malignancies:

  • Metastatic breast cancer (BR)
  • Metastatic ovarian cancer (OV)
  • Metastatic endometrial cancer (EM)
  • Metastatic cervical cancer (CX)

Breast Cancer Inclusion Criteria:

• Measurable metastatic disease (>1cm) in at least one site other than bone-only
• Progression on or failure to respond to at least one previous chemotherapy regimen for metastatic disease
• Progression on prior therapy with a hormonal agent if estrogen receptor or progesterone receptor positive, and/or with trastuzumab if HER2-neu positive. If patient has progressed through hormone or trastuzumab therapy only, must have received one chemotherapy regimen.

Ovarian Cancer Inclusion Criteria:

• Measurable metastatic disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST)
• Primary tumor must have been diagnosed histologically as either epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (not borderline or low malignant potential epithelial carcinoma).
• Subjects must have failed at least two previous chemotherapy regimens. Paclitaxel must have been a component of one or both regimens and cisplatin or carboplatin must have been a component of one or both regimens.

Endometrial Cancer Inclusion Criteria:

• Measurable metastatic disease
• Histologically proven recurrent or persistent endometrial cancer that is not amenable to curative treatment with surgery and/or radiation therapy AND has failed 2 previous treatment regimens

Cervical Cancer Inclusion Criteria:

• Measurable metastatic disease
• Histologically proven recurrent or persistent squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix that is not amenable to curative treatment with surgery and/or radiation therapy AND has failed 2 previous treatment regimens.

Exclusion Criteria:

• Had/have the following prior/concurrent therapy:

  • Systemic corticosteroids (oral or injectable) within 7 days of first dose of 852A (topical or inhaled steroids are allowed)
  • Investigational drugs/agents within 14 days of first dose of 852A
  • Immunosuppressive therapy, including cytotoxic agents within 14 days of first dose of 852A (nitrosoureas within 30 days of first dose)
  • Drugs known to induce QT interval prolongation and/or induce Torsades de pointes unless best available drug required to treat life-threatening conditions
  • Radiotherapy within 3 weeks of the first dose of 852A
  • Hematopoietic cell transplantation within 4 weeks of first dose of 852A
  • Evidence of active infection within 3 days of first dose of 852A
  • Active fungal infection or pulmonary infiltrates (prior treated disease stable for 2 weeks is allowable)
  • Cardiac ischemia, cardiac arrhythmias or congestive heart failure uncontrolled by medication
  • History of, or clinical evidence of, a condition which, in the opinion of the investigator, could confound the results of the study or put the subject at undue risk
  • Uncontrolled intercurrent or chronic illness
  • Active autoimmune disease requiring immunosuppressive therapy within 30 days
  • Active coagulation disorder not controlled with medication
  • Pregnant or lactating
  • Concurrent malignancy (if in remission, at least 5 years disease free) except for localized (in-situ) disease, basal carcinomas and cutaneous squamous cell carcinomas that have been adequately treated
  • Any history of brain metastases or any other active central nervous system (CNS) disease

Contacts and Locations

Locations

United States, Minnesota

Masonic Cancer Center, University of Minnesota

Minneapolis, Minnesota, United States, 55455

Sponsors and Collaborators

Masonic Cancer Center, University of Minnesota

Pfizer

Investigators

• Principal Investigator: Sarah Cooley, MD; Masonic Cancer Center, University of Minnesota
• Principal Investigator: Melissa A. Geller, MD; Masonic Cancer Center, University of Minnesota

More Information

• Responsible Party: Melissa Geller, M.D., Masonic Cancer Center, University of Minnesota
• ClinicalTrials.gov Identifier: NCT00319748
• Obsolete Identifiers: NCT00363493
• Other Study ID Numbers: 06US03IMP-852A; MT2006-02 ( Other Identifier: Blood and Bone Marrow Transplantation Program ); 2006LS005 ( Other Identifier: Masonic Cancer Center, University of Minnesota )
• First Posted: April 27, 2006
• Results First Posted: September 25, 2009
• Last Update Posted: August 26, 2019
• Last Verified: August 2019

Keywords provided by Masonic Cancer Center, University of Minnesota:

Breast; Ovarian; Endometrial; Cervical; Metastatic; 852A; IRM; Oncology; Metastatic Cervical Cancer; Metastatic Ovarian Cancer; Metastatic Breast Cancer; Metastatic Endometrial Cancer

Additional relevant MeSH terms:

Ovarian Neoplasms; Uterine Cervical Neoplasms; Endometrial Neoplasms; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Neoplasms, Female; Urogenital Neoplasms; Endocrine System Diseases; Gonadal Disorders; Uterine Neoplasms; Uterine Cervical Diseases; Uterine Diseases